Why the study?
Does the THRIVES multipronged intervention improve blood pressure control in patients with a recent stroke?
Does the THRIVES multipronged intervention improve blood pressure control in patients with a recent stroke?
This study protocol outlines a triple-blind randomized controlled trial to evaluate a multipronged intervention for improving blood pressure control among stroke survivors in Nigeria.
Answers are grounded in this paper and cite their sources.
THRIVES protocol tests multipronged BP intervention in Nigerian stroke survivors; leaves open efficacy in LMIC post-stroke populations.
RATIONALE: Stroke is the second-leading cause of death in low- and middle-income countries, but use of evidence-based therapies for stroke prevention in such countries, especially those in Africa, is extremely poor. This study is designed to enhance the implementation and sustainability of secondary stroke-preventive services following hospital discharge. AIM/HYPOTHESIS: The primary study aim is to test whether a Chronic Care Model-based initiative entitled the Tailored Hospital-based Risk reduction to Impede Vascular Events after Stroke (THRIVES) significantly improves blood pressure control after stroke. DESIGN: This prospective triple-blind randomized controlled trial will include a cohort of 400 patients with a recent stroke discharged from four medical care facilities in Nigeria. The culturally sensitive, system-appropriate intervention comprises patient report cards, phone text messaging, an educational video, and coordination of posthospitalization care. STUDY OUTCOMES: The primary outcome is improvement of blood pressure control. Secondary endpoints include control of other stroke risk factors, medication adherence, functional status, and quality of life. We will also perform a cost analysis of THRIVES from the viewpoint of government policy-makers. DISCUSSION: We anticipate that a successful intervention will serve as a scalable model of effective postdischarge chronic blood pressure management for stroke in sub-Saharan Africa and possibly for other symptomatic cardiovascular disease entities in the region.
No takes yet. Share an insight, caveat, or question.
Owolabi et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: